Monoclonal Gammopathy in ANCA-Negative Pauci-Immune Crescentic GN
Authors:
Open Access
- 25 July 2025
- journal article
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (12) , 2219-2228
Abstract
Key Points: Our study found a high prevalence of monoclonal gammopathy (MG) in patients diagnosed with ANCA-negative pauci-immune crescentic GN. Patients with MG showed a higher degree of fibrosis on kidney biopsy than those without MG with higher mortality rate. Our data suggest an association between MG and ANCA-negative pauci-immune crescentic GN, emphasizing this population's need for MG testing and monitoring. Background: In a small subset of patients with pauci-immune crescentic GN (PICGN), ANCA are not identified, and patients are referred to as having ANCA-negative vasculitis. The cause of the disease in this subset of patients has remained elusive. We explored the role of monoclonal gammopathy (MG) in those with ANCA-negative PICGN. Methods: We conducted a retrospective study and identified patients with PICGN who had undergone ANCA and monoclonal testing. Those positive for ANCA were excluded. Results: We identified 14 patients with ANCA-negative vasculitis, of whom eight (57%) tested positive for MG with a mean age of 60.3±12.2 years, 75% were female, and with a mean serum creatinine of 4.3±1.92 mg/dl. The most common monoclonal proteins were IgG ( n =4, 50%) and kappa ( n =4, 50%). One patient had diagnosis of multiple myeloma. Most common extra-renal manifestations were skin rash (leukocytoclastic vasculitis) and neuropathy. Kidney biopsy showed a higher degree of interstitial fibrosis and tubular atrophy compared with those without MG. The median follow-up time was 3.2 years, with 50% mortality in those with MG. Conclusions: More than 50% of the patients with ANCA-negative PICGN have MG, and patients present with more evidence of fibrosis on kidney biopsy, with higher mortality rate observed in our cohort. Monoclonal proteins may trigger the development of PICGN; their specific role in the pathogenesis of this disease needs further investigation.Keywords
This publication has 59 references indexed in Scilit:
- The Utility of Myeloperoxidase Immunostaining to Characterize Immune Deposits in Patients With Crescentic GlomerulonephritisKidney International Reports, 2025
- The clinical value of monoclonal protein in ANCA-associated vasculitis with renal involvementInternational Urology and Nephrology, 2023
- Molecular mechanisms and therapeutic target of NETosis in diseasesMedcomm, 2022
- The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significanceAmerican Journal of Hematology, 2021
- NETosis in Rheumatic DiseasesCurrent Rheumatology Reports, 2021
- Measuring Circulating Complement Activation Products in Myeloperoxidase– and Proteinase 3–Antineutrophil Cytoplasmic Antibody–Associated VasculitisArthritis & Rheumatology, 2019
- Thrombotic microangiopathy associated with monoclonal gammopathyKidney International, 2017
- Myeloperoxidase–Antineutrophil Cytoplasmic Antibody (ANCA)–Positive and ANCA‐Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient SubsetsArthritis & Rheumatology, 2016
- Renal participation of myeloperoxidase in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritisKidney International, 2015
- ANCA-negative pauci-immune crescentic glomerulonephritisNature Reviews Nephrology, 2009